PELL Bio-Med Technology Co (TPE:6949) Asset Turnover: 0.00 (As of Dec. 2025)


TPE:6949 PELL Bio-Med Technology Co Ltd TPE:6949
13 GF Score
Price NT$871.00
! 5 Warning Signs
View Full Analysis

What is PELL Bio-Med Technology Co Asset Turnover?

PELL Bio-Med Technology Co TPE:6949 +1.75% 13 Asset Turnover is 0.00 as of Dec. 2025. GuruFocus rates TPE:6949 with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. PELL Bio-Med Technology Co's Revenue for the three months ended in Dec. 2025 was NT$6.07 Mil. PELL Bio-Med Technology Co's Total Assets for the quarter that ended in Dec. 2025 was NT$1,866.00 Mil. Therefore, PELL Bio-Med Technology Co's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. PELL Bio-Med Technology Co's annualized ROE % for the quarter that ended in Dec. 2025 was -51.10%. It is also linked to ROA % through Du Pont Formula. PELL Bio-Med Technology Co's annualized ROA % for the quarter that ended in Dec. 2025 was -32.57%.


PELL Bio-Med Technology Co  (TPE:6949) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

PELL Bio-Med Technology Co's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-607.828/1189.5405
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-607.828 / 24.276)*(24.276 / 1865.9995)*(1865.9995/ 1189.5405)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2503.82 %*0.013*1.5687
=ROA %*Equity Multiplier
=-32.57 %*1.5687
=-51.10 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

PELL Bio-Med Technology Co's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-607.828/1865.9995
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-607.828 / 24.276)*(24.276 / 1865.9995)
=Net Margin %*Asset Turnover
=-2503.82 %*0.013
=-32.57 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


PELL Bio-Med Technology Co Asset Turnover Related Terms


PELL Bio-Med Technology Co Asset Turnover Historical Data

* Premium members only.

The historical data trend for PELL Bio-Med Technology Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PELL Bio-Med Technology Co Asset Turnover Chart

PELL Bio-Med Technology Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
0.04 0.02 0.02 0.01 0.02

PELL Bio-Med Technology Co Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.01 0.00 0.01 0.00

TPE:6949 vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, PELL Bio-Med Technology Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PELL Bio-Med Technology Co Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PELL Bio-Med Technology Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where PELL Bio-Med Technology Co's Asset Turnover falls into.


TPE:6949
13GF Score
PELL Bio-Med Technology Co Ltd TPE:6949
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PELL Bio-Med Technology Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

PELL Bio-Med Technology Co's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=31.424/( (1744.832+2112.225)/ 2 )
=31.424/1928.5285
=0.02

PELL Bio-Med Technology Co's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=6.069/( (1619.774+2112.225)/ 2 )
=6.069/1865.9995
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
PELL Bio-Med Technology Co (TPE:6949) has a Asset Turnover of 0.00 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on PELL Bio-Med Technology Co and its competitors.
Is PELL Bio-Med Technology Co's Asset Turnover too high?
PELL Bio-Med Technology Co's current Asset Turnover is 0.00. Overall, PELL Bio-Med Technology Co has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does PELL Bio-Med Technology Co's Asset Turnover compare to VRTX and REGN?
PELL Bio-Med Technology Co's Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on PELL Bio-Med Technology Co and its competitors. PELL Bio-Med Technology Co's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PELL Bio-Med Technology Co stock overvalued right now?
PELL Bio-Med Technology Co (TPE:6949) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. PELL Bio-Med Technology Co's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For PELL Bio-Med Technology Co (TPE:6949), the current Asset Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PELL Bio-Med Technology Co Business Description

Address No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, TWN
PELL Bio-Med Technology Co Ltd is a company engaged in the research and development and application of autologous T Cell Therapy (Adoptive T Cell Therapy), CAR-T (Chimeric Antigen Receptor T cell), and Gene-Modified Adipose-Derived Stem Cell (Gene-Modified Adipose-Derived Stem Cell). The company's segments includes Cell products, Consulting services, and Others.
13GF Score

Get the complete analysis for TPE:6949

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$871.00
Price